Vera Therapeutics (VERA) Change in Accured Expenses (2020 - 2026)

Vera Therapeutics (VERA) has 7 years of Change in Accured Expenses data on file, last reported at -$437000.0 in Q1 2026.

• Quarterly Change in Accured Expenses rose 90.86% year-over-year to -$437000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $18.8 million (up 358.67% YoY) and the FY2025 annual result came in at $14.4 million, up 100.92% from the prior year.
• Change in Accured Expenses eased to -$437000.0 in Q1 2026, from $7.2 million in the prior quarter.
• In the past five years, Change in Accured Expenses ranged from a high of $8.1 million in Q2 2025 to a low of -$4.8 million in Q1 2025.
• A 5-year average of $1.5 million and a median of $474000.0 in 2022 frame the typical range for Change in Accured Expenses.
• Annual changes were most pronounced in 2022 — Change in Accured Expenses tumbled 2964.29% — and 2024, when it surged 776.68%.
• Tracing VERA's Change in Accured Expenses over 5 years: stood at $4.7 million in 2022, then slumped by 122.21% to -$1.1 million in 2023, then sank by 257.4% to -$3.8 million in 2024, then surged by 291.35% to $7.2 million in 2025, then plunged by 106.06% to -$437000.0 in 2026.
• The last three Change in Accured Expenses figures came in at -$437000.0 (Q1 2026), $7.2 million (Q4 2025), and $3.9 million (Q3 2025), per Business Quant data.